Overall impact
B (61)

Commentary

Pulmonx is a strong overall performer. With a 'B' rating of 61.2 for overall impact (65th percentile compared to all companies), Pulmonx ranks 102nd out of 155 industry peers, behind American Shared Hospital Services, Accuray, Avinger and 98 others, and ahead of Hologic, Top Glove Corporation, Bioventus and 50 others. On top material causes for Pulmonx's industry (Healthcare Equipment), Pulmonx performs well in Improved Mental Health (86.0 score), Access to Affordable Healthcare (95.9), Child and Maternal Health (95.9) and 1 other cause where it received an 'A' score and performs poorly in Technology Innovation (17.2 score), Accountable Institutions (35.7), Free, Secure Flow of Information (33.5) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause LUNG
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1995
Employees
296
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
Ca, United States
Share classes
LUNG
Description
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Material causes
Ethos considers the following causes material for Pulmonx, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.